Back to top
more

Myomo (MYO)

(Delayed Data from AMEX)

$4.90 USD

4.90
233,827

+0.09 (1.87%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $4.87 -0.03 (-0.61%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Products

Zacks News

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Moves 5.5% Higher: Will This Strength Last?

Myomo, Inc. (MYO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 17.39% and 31.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 21.28% and 14.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic

Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test

BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

Boston Scientific (BSX) Hurt by Product Recall, Conversion

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging

Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.

Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance

Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.

Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout

Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.

Sriparna Ghosal headshot

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Expected to Beat Earnings Estimates: Should You Buy?

Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth

Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.

QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe

QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark

Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.

Align (ALGN) Rides on Volume Expansion Despite Cost Concerns

We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.